Lytix Biopharma Q1 net loss widens to NOK 25.95 million

• Lytix Biopharma posted a Q1 operating loss of NOK 26.8 million, widening from NOK 13.44 million a year earlier, while the period loss deepened to NOK 25.95 million from NOK 12.92 million.
• Total operating expenses climbed to NOK 26.8 million from NOK 13.44 million, due to higher direct R&D costs tied to the completion of the ATLAS-IT-05 study, strategic commercial assessments, and increased corporate activity.
• Cash and short-term financial investments totaled NOK 120 million at quarter-end following two Q1 capital raises with gross proceeds of NOK 77.3 million.
• NeoLIPA in neoadjuvant melanoma reached 74% enrollment with top-line results still expected in H2 2026, while an FDA meeting is scheduled in H2 2026 to align on a proposed Phase III plan ahead of a registrational study start in 2027.
• Partner Verrica plans to start a Phase III registrational trial for VP-315 (ruxotemitide) in basal cell carcinoma in 2026, while Lytix said it remains open for partnerships and is preparing LTX-401 for clinical entry in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lytix Biopharma ASA published the original content used to generate this news brief on May 21, 2026, and is solely responsible for the information contained therein.